Announcement

THE GLOBAL PLASMA FRACTIONATION LANDSCAPE THROUGH 2032

The report entitled The Global Plasma Fractionation Landscape Through 2032 is now available. It updates our report completed over two years ago with a complete listing of all the organizations that fractionate human plasma into therapeutic proteins in each country and globally. For each of the more than 80 fractionation facilities that are either operational or currently under construction, the location, fractionation capacity, throughput and utilization are identified on an annual basis both historically (starting in 2010) and on a forecasted basis from 2024 to 2032.

The subscriber will gain insights into the plasma fractionation capacities and throughputs of all manufacturers across all global geographies, both historically and into the future.  This information is the vital starting basis for forecasting the volume, valuation and geographic risks of production for all plasma proteins, in particular the future production of polyvalent immunoglobulin and albumin products.

The report’s forecast of worldwide plasma fractionation and throughput capacity to the year 2032 is based on the Marketing Research Bureau’s primary research as well as its extensive industry contacts.  The top global manufacturers are individually profiled, with a focus on expansion activities and the rationale behind them.

Additionally, this report identifies the plasma volumes for all contract fractionation contracts between manufacturers and countries from which plasma is collected and to which finished products are returned, providing insights into the regional and global scope of the contract fractionation business.  Price-per-liter fees are also detailed when available.